A new #JACC State-of-the-Art Review examines the interpretation of hs-cTn levels, common non-acute coronary syndrome conditions associated with troponin elevation and emerging advances that may improve diagnostic specificity. https://t.co/EjjfVKaqlQ
The proposed left atrium (LA) staging framework offers mechanistic insights into how the LA adapts to progressive diastolic dysfunction in #cvHCM. It is associated w/ a graded risk of NOAF and may help tailor AF surveillance strategies.
Learn more: https://t.co/0JcnUXXs3h #JACC
ACACIA-HCM trial topline results - aficamten in nHCM. Incredibly proud and thankful to our patients and team for their commitment and hard work. This represents the first effective treatment for patients with nHCM. looking forward to seeing the full results.
#CardioTwitter
Danicamtiv enhanced cardiac myosin function in vitro and was generally well tolerated in #DCM. Echo findings suggest improved contractility, with strongest responses in #MYH7 and TTN cohorts https://t.co/OS5zxv1hLT #JACC#cvDCM
RBM20 cardiomyopathy carries a more significant burden at a younger age, and an accelerated course compared to TTN cardiomyopathy
https://t.co/C2807uJKO1
#CardioTwitter
Limiting fluid intake may have no benefit for patients with #HeartFailure, according to findings from the FRESH-UP study presented during a Late-Breaking Clinical Trial session at #ACC25.
Check out the key findings ➡️ https://t.co/hVqEY34Uie
📅 The A Coruña Hypertrophic Cardiomyopathy Congress is Back!
🗓 September 18-19, 2025
🔬 Experts from 🇦🇷 🇦🇺 🇩🇪 🇪🇸 🇫🇷 🇬🇧 🇮🇹 🇳🇱 🇵🇹 🇺🇸 @seccCFyGenetCV@secardiologia
🔗 https://t.co/NQHuCS0lBW
🧬 24% of patients with heritable arrhythmias & cardiomyopathies carry a disease-causing variant—but only 8% see changes in clinical management. How do we close the gap? Read the study: https://t.co/AhDq8BbqFR
#JACC#Genetics#CardioScience#PrecisionMedicine#cvGenetics
Cardiopulmonary exercise testing (CPET) has a unique role in the assessment of cardiopulmonary disease. @BrazileTiffany and colleagues review key CPET variables, protocols and clinical indications. https://t.co/0Wgjt1XLCf
Heart failure with preserved ejection fraction is noted for symptoms of heart failure, LVEF of at least 50%, and cardiac or structural abnormalities. Treatment includes diuretics and SGLT2 inhibitors. Learn more: https://t.co/b6tbHu2J97
🔬New in @JACCJournals: HCM diagnosis criteria show unexpected demographic bias. Study of 50,000+ hearts reveals current thresholds create 8:1 male-female ratio
Proposing demographic-adjusted thresholds to improve diagnosis🫀
https://t.co/GoRmh9eGmC
@UCL_ICS@NHSBartsHealth